World-leading infection prevention.

AMR Bio is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

Find Out More About Us

Prevention is better than cure.

AMR Bio is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

Find Out More About Our Pipeline

Novel, preventative medicines for the hospital market.

AMR Bio is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

Find Out More About Our Target Markets

Events

18 September 2024

ESCMID/ASM

18 March 2024

BIO-Europe Spring

08 January 2024

Biotech Showcase
Latest News

05 June 2026

AMR Bio Contributes to US National Action Plan on Combating Antibiotic-Resi ...

03 June 2026

FDA Confirmation of Full Regulatory Transfer

Share Price

XF-73 Nasal

XF-73 Nasal is the lead asset from the company’s XF platform ...

…and is a novel compound being developed for the prevention of post-surgical Staphylococcal infections.
Learn More

XF-73 Dermal

The company is also developing a dermal formulation of XF-73 Dermal for the treatment of bacterial skin infections ...

…and has been supported by the US government’s National Institute for Allergy and Infectious Diseases, (part of the US National Institutes of Health).
Learn More